The loss of ARID1A expression as determined by IHC and predicted by abrogating mutation rates as designated by “(%)” is illustrated in the following tumor types: ~14–25% (2.4%) of gastric cancers (141), 15–34% (36.3%) of endometrial carcinomas (129, 132, 149), 0–2% (0.5%) of renal cell cancers (121, 133), 60–65% (2.0%) of breast cancers (122–124, 150, 151), and 10% (2.8%) of squamous cell lung cancers (128). Here, ARID1A is linked to breast carcinoma.